SynthesisFrontiers in oncology2025
Combined imaging and serum biomarkers in CEUS-guided microwave ablation for hepatocellular carcinoma: A meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multiparametric Abdominal Ultrasound as a Source of Imaging Biomarkers in Predictive and Personalized Medicine: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the efficacy of a treatment strategy that actively integrates imaging features and serum biomarkers into contrast-enhanced ultrasound (CEUS)-guided microwave ablation (MWA) for hepatocellular carcinoma (HCC). Methods: A comprehensive literature search was conducted, and randomized controlled trials (RCTs) meeting the inclusion criteria were selected. The methodological quality of the included studies was assessed using the Cochrane Risk of Bias Tool, and RevMan 5.3 software was employed for meta-analysis. The primary endpoints included complete tumor ablation rate, local recurrence rate (LRR), local progression rate (LPR), recurrence-free survival (RFS), and complication rate. Results: A total of seven RCTs involving 1,039 HCC patients (407 in the treatment group, 632 in the control group) were included. Meta-analysis demonstrated the following: The complete ablation rate was significantly higher in the treatment group than in the control group (risk ratio [RR] = 1.06; 95% confidence interval [CI] = [1.01, 1.10]; Conclusion: CEUS-guided MWA combined with imaging features and serum biomarkers is associated with significant improvements in complete tumor ablation rates and a reduction in local recurrence. This strategy provides evidence-based support for optimizing precision local control in HCC, but its impact on long-term survival requires validation through future studies with extended follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.